The two subgroups appear to have a distinct molecular profile.; specifically, subgroup A as NF-PanNETs with noticeably worse outcome, while subgroup B, represented by insulinomas, have a good prognosis and are usually not methylated at the PDX1 promoter. This evidence concerns the gene PDX1 and pancreatic insulinoma.